A Large, International, Randomized, Placebo-controlled Trial to Assess the Impact of Dabigatran (a Direct Thrombin Inhibitor) and Omeprazole (a Proton-pump Inhibitor) in Patients Suffering Myocardial Injury After Noncardiac Surgery
Overview
- Phase
- Phase 3
- Intervention
- Dabigatran
- Conditions
- Myocardial Injury After Noncardiac Surgery (MINS)
- Sponsor
- Population Health Research Institute
- Enrollment
- 1754
- Locations
- 82
- Primary Endpoint
- Major upper gastrointestinal complication (for Omeprazole)
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
Patients who have myocardial injury after noncardiac surgery are at a higher risk of dying than those who do not. One in 10 patients with myocardial injury will die within 30 days of surgery. This risk of death exists up to one year after myocardial injury. There are currently no treatments or guidelines available for heart injury after surgery, but there is evidence that taking a blood-thinner can prevent some of the deaths, both in the short and long-term. The purpose of this trial is to test the effect of two drugs (dabigatran and omeprazole) that may prevent mortality, major cardiovascular complications and major upper gastrointestinal bleeding in patients who have had myocardial injury after noncardiac surgery.
Detailed Description
Myocardial injury is the most common major vascular complication after noncardiac surgery. Worldwide approximately 10 million adults annually suffer a perioperative myocardial injury. This figure for perioperative myocardial injury represents 15-20% of all cases of myocardial infarction in all settings. Myocardial injury after noncardiac surgery carries a poor prognosis and is an independent predictor of 30-day and 1-year mortality. Myocardial injury after noncardiac surgery (MINS) differs from non-operative myocardial infarction in two ways; it has a poorer prognosis (patients suffering MINS are 2 times more likely to die within 30 days compared to non-operative myocardial infarction in the emergency room) and paradoxically its treatment is less intensive. This difference in the intensity of treatment is likely influenced by several factors including: (1) a majority of patients suffering MINS do not experience ischemic symptoms, potentially influencing physicians' perception of the severity of the event; (2) there is debate as to the pathophysiology of MINS (although emerging evidence does suggest that coronary arterial thrombosis is an important mechanism of MINS); and (3) no randomized controlled trial (RCT) has evaluated an intervention to manage MINS, and hence physicians are uncertain about the risk-benefit ratio of potential interventions (e.g., interventions that are effective in the management of non-operative myocardial infarction). From a human and economic perspective, it is a tragedy that some patients undergoing noncardiac surgery for important reasons (e.g., to obtain a cure of their cancer or to become mobile after a new prosthetic joint) fail to obtain these benefits, because they suffer MINS that ultimately takes their life. There is an urgent need for clinical trials to identify effective therapies to improve the outcomes of patients suffering MINS. There exists promising laboratory, autopsy, imaging, operative, and non-operative data suggesting that patients suffering MINS will benefit from anticoagulant therapy. Dabigatran (a direct thrombin inhibitor) warrants evaluation in the management of MINS. The major limitation of anticoagulation therapy is bleeding, and gastrointestinal bleeding represents a substantial proportion of these complications. Gastrointestinal bleeding is important in its own right, but also because it leads to cessation of anticoagulant therapy which may lead to breakthrough myocardial infarction. Omeprazole (a proton pump inhibitor) is efficacious in preventing upper gastrointestinal bleeding in patients with coronary artery disease who are taking dual antiplatelet therapy, and may benefit patients receiving anticoagulation therapy after suffering MINS. We will undertake a large international RCT to determine the impact of dabigatran in patients who have suffered MINS. We will use a partial factorial design (for patients not taking a proton pump inhibitor) to determine the impact of omeprazole in this setting. We call this RCT the Management of myocardial injury After NoncArdiac surGEry (MANAGE) Trial.
Investigators
P.J. Devereaux
Professor, Medicine (Cardiology) and Clinical Epidemiology and Biostatistics, McMaster University
Population Health Research Institute
Eligibility Criteria
Inclusion Criteria
- •Patients are eligible if they:
- •have undergone noncardiac surgery;
- •are ≥45 years of age;
- •have suffered MINS based upon fulfilling one of the following criteria: A. Elevated troponin or CK-MB measurement with one or more of the following defining features i. ischemic signs or symptoms (i.e., chest, arm, neck, or jaw discomfort; shortness of breath, pulmonary edema); ii. development of pathologic Q waves present in any two contiguous leads that are ≥30 milliseconds; iii. electrocardiogram (ECG) changes indicative of ischemia (i.e., ST segment elevation \[≥2 mm in leads V1, V2, or V3 OR ≥1 mm in the other leads\], ST segment depression \[≥1 mm\], OR symmetric inversion of T waves ≥1 mm) in at least two contiguous leads; iv. new LBBB; or v. new or presumed new cardiac wall motion abnormality on echocardiography or new or presumed new fixed defect on radionuclide imaging B. Elevated troponin measurement after surgery with no alternative explanation (e.g., pulmonary embolism, sepsis) to myocardial injury; AND
- •provide written informed consent to participate within 35 days of suffering their MINS.
Exclusion Criteria
- •Patients meeting any of the following criteria will be excluded:
- •hypersensitivity or known allergy to dabigatran;
- •history of intracranial, intraocular, or spinal bleeding;
- •hemorrhagic disorder or bleeding diathesis;
- •known hepatic impairment or liver disease expected to have an impact on survival;
- •condition that requires therapeutic dose anticoagulation (e.g., prosthetic heart valve, venous thromboembolism, atrial fibrillation);
- •currently using or plan to initiate rifampicin, cyclosporine, itraconazole, tacrolimus, ketoconazole, or dronedarone;
- •women who are pregnant, breastfeeding, or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study;
- •investigator considers the patient unreliable regarding requirement for study follow-up or study drug compliance; OR
- •previously enrolled in the MANAGE Trial.
Arms & Interventions
Dabigatran
Dabigatran 110 mg capsule taken twice daily
Intervention: Dabigatran
Omeprazole
Omeprazole 20 mg capsule taken once daily
Intervention: Omeprazole
Placebo (dabigatran)
Dabigatran placebo taken twice daily
Intervention: Placebo (for Dabigatran)
Placebo (omeprazole)
Omeprazole placebo taken once daily
Intervention: Placebo (for Omeprazole)
Outcomes
Primary Outcomes
Major upper gastrointestinal complication (for Omeprazole)
Time Frame: Average of 1 year follow-up
A composite of the number of patients suffering overt gastroduodenal bleeding, overt upper gastrointestinal bleeding of unknown origin, or upper gastrointestinal perforation.
Major vascular complication (for Dabigatran)
Time Frame: Average of 1 year follow-up
A composite of the number of patients suffering vascular mortality, nonfatal myocardial infarction, nonfatal non-hemorrhagic stroke, nonfatal peripheral arterial thrombosis, nonfatal amputation, and nonfatal symptomatic venous thromboembolism (i.e., symptomatic pulmonary embolism or symptomatic proximal deep venous thrombosis).
Secondary Outcomes
- Individual secondary outcomes for Dabigatran(Average of 1 year follow-up)
- Major vascular complication for Omeprazole(Average of 1 year follow-up)
- Individual secondary outcomes for Omeprazole(Average of 1 year follow-up)
- Upper gastrointestinal complication for Omeprazole(Average of 1 year follow-up)
- Safety outcomes for Dabigatran(Average of 1 year follow-up)
- Safety outcomes for Omeprazole(Average of 1 year follow-up)